With over ten years of data on Cesium Blu, researchers continue to study its value in powering modern brachytherapy. ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online.
A Matched Pair Analysis Of Clinical Outcomes After Intracavitary Cesium-131 Brachytherapy Versus Stereotactic Radiosurgery For Resected Brain Metastases
Conclusion: Patients with brain metastases and GTR were more likely to achieve LC with Cs-131 brachytherapy as compared with SRS. These retrospective data provide evidence for Cs-131 to reduce LR for BM following GTR, with minimal toxicity, and would support a prospective, randomized study.
Report of a Large Cohort of Intermediate-Risk Prostate Cancer Patients Treated with Cs-131 Brachytherapy
Conclusion: The FIR subgroup is a distinct entity from the UIR subgroup with excellent outcomes when treated with Cs-131 PB alone. UIR patients have excellent outcomes with combined EBRT + PB. The majority of UIR patients do not require ADT, though the group that would benefit still needs to be defined.
Cs-131 Intracavitary Brachytherapy as an Adjunct to Maximal Safe Resection for Locally Recurrent High-Grade Glioma
Conclusion: Cs-131 seed implantation using a bioabsorbable collagen matrix delivery device is a feasible method of achieving dose-escalated re-irradiation starting at time of implantation.
Conclusion: IORT via brachytherapy mesh placement at time of resection for high-risk malignancies appears feasible and effective across multiple sites and histologies. Locoregional disease control rates after R1 resections were adequate and treatment-related toxicities were minimal.
The Effect of Positive Biopsy Cores on the Prognosis of Patients with Intermediate Risk Prostate Cancer Treated with Cs-131 Prostate Brachytherapy
Conclusion: In patients treated with Cs-131 PB, those with GG2 disease have an excellent prognosis, regardless of % of biopsy cores positive for PC. Patients with GG3 and < 50% of cores positive also have an excellent prognosis, while patients with GG3 and >50% of cores positive seem to have a worse prognosis and likely would benefit from more aggressive treatment, such as trimodality therapy.